- Home
- WNEB vs SKYE Comparison
WNEB vs SKYE Comparison
Compare WNEB & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- SKYE
- Stock Information
- Founded
- WNEB 1853
- SKYE 2012
- Country
- WNEB United States
- SKYE United States
- Employees
- WNEB N/A
- SKYE N/A
- Industry
- WNEB Savings Institutions
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- SKYE Health Care
- Exchange
- WNEB Nasdaq
- SKYE Nasdaq
- Market Cap
- WNEB 165.5M
- SKYE 172.9M
- IPO Year
- WNEB N/A
- SKYE N/A
- Fundamental
- Price
- WNEB $8.74
- SKYE $5.80
- Analyst Decision
- WNEB Hold
- SKYE Strong Buy
- Analyst Count
- WNEB 4
- SKYE 5
- Target Price
- WNEB $8.50
- SKYE $18.40
- AVG Volume (30 Days)
- WNEB 38.8K
- SKYE 147.7K
- Earning Date
- WNEB 10-22-2024
- SKYE 11-09-2024
- Dividend Yield
- WNEB 3.18%
- SKYE N/A
- EPS Growth
- WNEB N/A
- SKYE N/A
- EPS
- WNEB 0.63
- SKYE N/A
- Revenue
- WNEB $74,435,000.00
- SKYE N/A
- Revenue This Year
- WNEB N/A
- SKYE N/A
- Revenue Next Year
- WNEB $5.16
- SKYE N/A
- P/E Ratio
- WNEB $13.77
- SKYE N/A
- Revenue Growth
- WNEB N/A
- SKYE N/A
- 52 Week Low
- WNEB $6.00
- SKYE $1.44
- 52 Week High
- WNEB $9.25
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- WNEB 62.55
- SKYE 47.89
- Support Level
- WNEB $8.45
- SKYE $5.71
- Resistance Level
- WNEB $8.90
- SKYE $7.11
- Average True Range (ATR)
- WNEB 0.19
- SKYE 0.62
- MACD
- WNEB -0.04
- SKYE 0.01
- Stochastic Oscillator
- WNEB 53.70
- SKYE 7.22
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.